CytRx Corporation
11726 San Vicente Boulevard, Suite 650
Los Angeles, California 90049
March 23, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Securities and Exchange Commission
Washington, D.C. 20549
| Re: | CytRx Corporation Registration Statement on Form S-1, as amended Initially filed on August 4, 2021, as amended on March 23, 2022 File No. 333-258453 (the “Registration Statement”) Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, CytRx Corporation (the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement, as amended, so that it may become effective at 4:00 p.m., Eastern Time, on March 25, 2022, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
| Very truly yours, | ||
| CytRx Corporation | ||
| By: | /s/ Dr. Stephen Snowdy | |
| Dr. Stephen Snowdy | ||
| Chief Executive Officer | ||
| cc: | Rick A. Werner, Esq., Haynes and Boone, LLP |